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Peanut allergy is one of the most prevalent and deadliest food allergies.  As public 
awareness has increased about the dangers of food allergies, there has been a 
corresponding increase in the research on peanut allergies.  Significant increases in 
practical applications of our knowledge have occurred in the last few decades including 
questions that have been answered as to the best routes and methods of exposure to 
peanuts, there are innovative new therapies for possibly resolving peanut allergies, and 
cell based assays can now utilize components of peanuts that have significantly better 
predictive power and reproducibility than the previous whole peanut extracts. The next 
step is to be able to correlate laboratory tests to the severity of peanut allergy symptoms 
without having to expose the patients to the suspected food and risk urticaria, 
anaphylaxis, or even death.  Basophil Activation Testing (BAT) is a promising way to do 
this and to help improve the correct diagnosis of potentially severe, life-threatening 
peanut allergy.  The results from this study showed that BAT tests were able to correctly 
predict the outcome of food challenges as well as discriminate between peanut-sensitized 
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INTRODUCTION TO PEANUTS 
Peanut History 
Peanuts originally came from South America and have been cultivated for 
thousands of years.  Some of the earliest domesticated peanut seeds date back to 2000-
3000 B.C. and peanut-styled ceramic pottery has been discovered in pre-Incan Indian 
cultures from circa 500-1000 A.D.1  They have also been found entombed with ancient 
Peruvian mummies and appear to have been used in sacrificial offerings.2 
Peanuts have spread around the world and can be found growing in almost any 
region.  They were originally brought to North America by African slaves who used them 
to supplement their diets, and they were later grown and used as food for livestock in the 
1700s.1  Peanuts started gaining popularity in the 1800s when the Civil War broke out 
and food was scarce and then later when the Barnum Circus started selling roasted 
peanuts as they traveled around the United States.2 
There was also an increase in peanut production due to George Carver 
Washington. He and other agricultural researchers encouraged Southern farmers to plant 
peanuts as a way to increase the amount of nitrogen in the soils which had been greatly 
depleted over the years by growing crops of cotton.  He is credited with discovering at 






Peanut Plants and Varieties 
 Peanuts are a legume that are grown underground in pods by a flowering plant in 
the pea family (Fabaceae).  There are four basic types of commercial peanuts grown and 
eaten in the United States: Spanish, Virginia, Runner, and Valencia. Spanish peanuts 
have a high oil content and are more easily crushed. They are often turned into peanut 
butter. Virginia peanuts have a large kernel and are often sold unshelled or as shelled 
salted peanuts. Runners are technically a hybrid between Spanish and Virginia peanuts, 
but they have been used for many years and are often considered as a separate variety. 
Valencia are sweeter and are most often used for boiled peanuts. Studies have shown that 
all the varieties are similar in terms of total protein, and in the content of the two most 
allergenic proteins Ara h 1 and Ara h 2.3  Refer to Table 1.1 for a compilation of the exact 
percentage of proteins and attributes of the top four varieties.  
 
 
Table 1.1 Peanut Attributes of the Top Four Varieties in the United States 
 









Peanut Butter Boiled Peanuts, 
Roasted/Unshelled 
 
Attributes High oil 
content, “nutty” 
flavor 







27-29% 26-29% 24-28% 26-29% 
 
 
Ara h 1 
protein 
12-16% 15-16% 13-16% 14% 
 
 
Ara h 2 
protein 





 In general, peanut total protein has been found to make up 24-29% of the whole 
peanut with Ara h 1 accounting for 12-16% and Ara h 2 for 5.9-9.3% of the protein 
fraction. 
It is important to note that different countries do have different peanut breeding 
strains and it has been shown that the allergen content can vary somewhat; for example, 
one peanut line from India has a 7% Ara h 1 content whereas Nigeria has a peanut strain 
that has 18.5% Ara h 1.4  The different varieties of peanuts also have different expression 
patterns of the main allergens during seed development but the allergens are restricted to 
seed and are not found in the leaves, flowers, or roots of the peanut plant.5 
The method of preparation of peanuts has been shown to change the allergenicity.  
Roasting peanuts has been shown to increase allergenicity and can bind antipeanut 
antibodies at a 90-fold increase versus raw peanuts.6  In contrast, boiling or frying peanuts 
has been shown to decrease the allergenicity and has been suggested as a possible reason 
why peanut allergens are less prevalent in China and parts of the world where peanuts are 
commonly eaten boiled rather than roasted.7 
Peanut Components 
Historically, skin prick testing and serum IgE antibody testing has been done 
using the whole peanut extract, but this has been problematic over the years due to 
different manufacturers using different varieties of peanuts and different preparation 
methods (eg, raw versus roasted peanuts).  A newer method that has been gaining interest 
over the years is to break down the whole peanut into its different protein components.  





the past to differ between different manufacturers8 and can even possibly differ between 
lots.  Certain components are also only found in trace amounts in the whole peanut 
extract. By creating a test specifically for the peanut component instead of the whole 
extract, there can be greater standardization of test results.   
Since the amino acid sequences and protein structures of the peanut components 
are known, they can be replicated by using Escherichia coli (E. coli) strains or phages 
that have been given cDNA for the specific component.  This further eliminates 
variability and the risk of contamination of other peanut components that might be 
present if an extraction process using whole peanut is used.   
 These components have been labeled sequentially as Ara h 1, Ara h2, Ara h 3, and 
so forth.  The "Ara h" is derived from the scientific name for peanut, Arachis hypogaea.  
Table 1.2 lists the components that have been discovered and registered with the World 
Health Organization and International Union of Immunological Societies.  Ara h 4 is 
somewhat unique in that it was originally given its own designation but was later 
discovered to be an isoform of Ara h 3 and renamed Ara h 3.02.  Some components have 
been proven to be more important than others in eliciting the severity of peanut allergy.  
The most commonly studied and addressed components are Ara h1, Ara h2, Ara h3, Ara 
h6, Ara h8, and Ara h9. 
Ara h1 has been identified as a seed storage glycoprotein (7S vicilin-like 
globulin).  It forms a stable trimer and has several hydrophobic residues that are critical 
for IgE binding.9  While there are not differences in Ara h 1 levels between the main U.S. 
cultivars, there has been a difference described between the size and maturity of the 












Ara h 1 7S vicilin-like globulin Seed storage glycoprotein  
Ara h 2 2S albumin/conglutin Trypsin inhibitor 
Ara h 3 11S globulin/glycinin Trypsin inhibitor 
Ara h 4 11S globulin/glycinin (isoform of Ara h 3) 
Ara h 5 Profilin Cell motility/actin 
dynamics 
Ara h 6 2S albumin/conglutin   
Ara h 7 2S albumin/conglutin   
Ara h 8 PR-10 protein (Bet v 1-
homolog) 
Plant defense protein 
Ara h 9 Nonspecific lipid 
transfer protein 
Lipid transfer protein 
Ara h 10 16 kDa oleosin Lipid Storage 
Ara h 11 14 kDa oleosin Lipid Storage 
Ara h 12 Defensin Host defense peptides 
Ara h 13 Defensin Host defense peptides 
Ara h 14 17.5 kDa oleosin Lipid Storage 
Ara h 15 17 kDa oleosin Lipid Storage 
Ara h 16 Nonspecific lipid 
transfer protein 2 
Lipid transfer protein 
Ara h 17 Nonspecific lipid 
transfer protein 1 
Lipid transfer protein 
 
than smaller more immature peanuts.10  
As was previously mentioned, roasting increases the antigenicity of peanuts.  Ara 
h 1 in particular increases by 22-fold after roasting.10  It’s also been found that Ara h 1 
and Ara h 2 are more resistant to heat and gastric digestion after undergoing a Maillard 
reaction, a common nonenzymatic reaction that occurs in cooking/roasting that causes 
‘browning’ and gives food more flavor.6  In contrast to roasted peanuts, boiled and fried 
peanuts have been shown to have no detectable amounts of the Ara h 1 trimer form and 
markedly reduced amount of the Ara h 1 monomeric form.7 
Importantly, Ara h 1 peptides can change conformation at different pHs and it has 





make it to the small intestine’s higher pH environment can undergo conformational 
change and form large aggregates with newly uncovered allergen epitopes11 which might 
cause delayed allergic responses.  Once peanut protein reaches the intestinal epithelia, the 
way it gets absorbed is unique. In an experiment using Caco-2 cells (a human intestinal 
epithelial cell line), Ara h 1 and h 2 have been shown to disrupt the transmembrane tight 
junction proteins12 and, in essence, escape from the GI tract.  These results have been 
suggested as an explanation for the increased allergenicity of peanuts. 
Ara h 2 is a 2S albumin/conglutin protein that is known to function as a trypsin 
inhibitor.  It is considered the most predictive and accurate indicator of peanut allergy 
when compared to the other peanut components and whole peanut extract.  Nicoaou et al 
showed that it possessed significantly increased sensitivity and specificity compared to 
the whole peanut extract and the other peanut components. At levels of 0.35 kU/l, whole 
peanut had a sensitivity of 96.55% and specificity of 26.92%, but Ara h 2 had a 
sensitivity of 100%, and specificity of 96.08 %13 and has also been shown to be a more 
potent allergen then Ara h 1 in functional IgE-crosslinking assays.14  It has also been 
shown that heating of Ara h 2 may enhance its binding to intestinal epithelium cells, 
performed with the Caco-2 cell line, and that in mouse models, heated Ara h 2 induces 
significantly higher levels of IL-2 and IL-6 from splenocytes then unheated Ara h 2.15  
Comparison of fried and boiled peanuts versus roasted peanuts showed that unlike the 
Ara h 1, Ara h 2 had the same amount of protein and antigen in both preparations.  IgE-
binding to both Ara h 2 and h 3, however, was reduced in the fried and boiled peanuts7 
and roasting of Ara h 2 increased its trypsin inhibitory activity by 3.6 fold.16 





component antibodies indicating that IgE binding to Ara h 2 can be inhibited by 49-89% 
by adding Ara h 1 and Ara h3.17  Ara h 3 is an 11S globulin/glycinin protein that also 
functions as a trypsin inhibitor.  It also includes Ara h 4 which was originally given its 
own designation but was later found to be an isoform of Ara h3 and is now considered to 
be one antigen. Together, Ara h 1, h 2, and h 3 represent the most common peanut 
antigens found to cause significant peanut allergies.  IgE antibodies directed against these 
proteins are more indicative of severe peanut allergy and a greater risk of anaphylactic 
shock.18 
Ara h 5 is a profilin that helps with cell motility and actin dynamics. Tests for 
antibodies against Ara h 5 are not currently commercially available since it is considered 
a more minor peanut allergen. It has been reported that only 13% of patients allergic to 
peanuts are sensitized to Ara h 5.19 
Ara h 6 is a 2S albumin/conglutin that has a 59% amino acid sequence match to 
Ara h2.  Ara h 6 has been shown to be epitopically similar to Ara h 2 and that either one 
can restore allergenicity in whole peanut extract; consequentially, they have been labeled 
as “substantially redundant.”20  Ara h 6 has also been shown to have similar properties in 
comparison to Ara h 2 in that it is resistant to pepsin digestion and heat treatment.21  
Sensitization to Ara h 6 has been shown to be strongly correlated with Ara h 2 
sensitization (r = 0.861).22 Indeed some studies have reported that all patients with Ara h 
2 specificity showed matching Ara h 6 specificity,23 but larger studies have noted small 
numbers of patients 3/166 (2%) that have sensitization to only Ara h 6.24 
Ara h 7 is also a 2S albumin/conglutin like Ara h 2 and Ara h 6; however, it only 





moderately high sensitization rate of 43% in two different studies,24,19 it is not 
commercially available for routine laboratory testing.   
Ara h 8 is a Bet v 1 homolog panallergen.  Bet v 1 is one of the major antigenic 
proteins expressed by Birch trees (Betula verrucosa) and is considered a panallergen 
because of its similarity to other antigens expressed by fruits and other trees, especially 
those in the Fagales genus. One study, performed by Moverare et al, found that all of 
their patients who had Ara h 8 antibodies also had antibodies against birch pollen and 
they were highly correlated (p<0.0001).18   Bet v 1 has also been shown to inhibit SIgE 
binding to Ara h 8 in immoblotting and RAST inhibition assays.25  Patients that become 
sensitized to Bet v 1 and its homologs most commonly have cross-reactivity with 
allergens in peach, apple, celery, and carrot which are correlated with oral allergy 
syndrome.26 Ara h 8 has been studied and found to be indicative of mild to negligible 
peanut allergies when antibodies against Ara h 1, 2, and 3 are not present.27  It has also 
been shown that Ara h 8 antigenicity is actually decreased by 9-fold during roasting, as 
determined by inhibited IgE binding, and that the enzyme pepsin, found in the stomach, 
can completely destroy the antigenicity within 5 seconds.25 
Ara h 9 is a nonspecific lipid transfer protein that has some similarity to peach 
antigens (62-68% amino acid overlap).28  Ara h 9 is an interesting allergen in that it is 
considered significant in certain populations, specifically Mediterranean populations,28,29 
but is considered a more minor allergen in almost all other populations.  A recent study, 
however, has shown that Ara h 9 sensitization is linked to a higher prevalence of 
bronchospasms (26% vs 9%) and may be more significant than previously thought.30 





point. These allergens have been identified as either oleosin’s, defensin’s, or lipid transfer 
proteins.31 
Peanut Allergies and Sensitization Routes 
It was uncommon before the late 1800s for allergies to occur and studies done 
around 1870 showed “hay fever” as an emerging disease.32  Peanut allergies are reported 
to have started showing up in the early 1900s although most of the medical community’s 
focus was still on the more common food allergies like milk and eggs at that time.1  
Peanut allergies are currently a significant problem that affects approximately 1.2% of 
children, and over three million Americans are affected by peanut and/or tree nut 
allergies.33   Peanuts and tree nuts have been shown to account for more than 90% of all 
fatal anaphylactic reactions and approximately 100-200 people die every year in the 
United States from anaphylaxis due to accidental peanut ingestion.34,35   
There is a significant portion of the atopic population that is extremely allergic to 
peanuts and can have life-threatening reactions from very small amounts of peanut 
protein.  Peanut allergy has become a real fear for many parents as they try to keep their 
kids from developing it or from having life-threatening reactions if they do develop an 
allergy.  It is common to walk into schools, daycare centers, or cafeterias and see signs 
which ban peanuts or discourage peanuts from being brought into the area. One third of 
individuals allergic to peanuts also have allergies to tree nuts36 which is why tree nuts are 
usually included in the ‘bans’ as well. One recent study tried to investigate the spread and 
distribution of peanut protein in homes and in the school environment.  Their results 





hours after consumption and that the proteins can be aerosolized when the peanuts are 
being shelled.37  The risk of systemic reaction from skin contact to peanut butter has also 
been shown to be rather low in children with significant peanut allergies,38 indicating that 
the ‘ban’ on peanuts may be unnecessary in preventing life-threatening reactions.  
Reactions such as redness, itching, and wheals, however, are still seen in children with 
significant peanut allergies upon contact with peanut butter which might be avoided with 
peanut bans.  
The best way to stop an allergy is to prevent it from occurring.  For a long time, it 
was debated as to whether or not children should be exposed to peanuts from an early 
age.  It was thought that if you prevent exposure, you could prevent the allergy.  Starting 
in the 1990s, medical professionals such as the American Academy of Pediatrics started 
recommending avoidance diets for young children.  Pregnant or nursing mothers were 
also advised to avoid peanuts as well to limit the children’s exposure through secondary 
sources.  These avoidance diets for mothers and children did not slow the increase in 
peanut allergies and questionnaire studies done by Sicherer et al showed that peanut 
allergy in children actually increased from 0.4% in 1997 to 0.8% in 2002 and then to 
1.4% in 2008.39 
Several studies started to look at the routes of peanut sensitization and had 
suggestive results that early oral exposure had a protective effect.40  Most of these studies 
were questionnaire based, however, or included only a small population size. To come up 
with a definitive answer, the Learning Early About Peanuts (LEAP) study was 
established.  This study enrolled 640 at-risk children who already had an egg allergy or 





avoidance diet and followed them for 5 years.  The recently published LEAP results 
indicated a significant and definitive decrease in peanut allergies (13.7 % vs. 1.9%) in 
children that ate peanuts on a regular basis.41 Early exposure through the skin by 
application of peanut-oil containing creams; however, instead of by dietary exposure, has 
been linked to an increase in peanut allergies.42 
Older studies reported no effect of maternal peanut consumption on their 
children’s development of peanut sensitization.40,42  There have also been recent studies, 
however, suggesting that consumption of peanuts and tree nuts by nonallergic mothers 
during pregnancy and while nursing lowered the risk of peanut and tree nut allergies in 
their children.43 
Other environmental factors like Vitamin D levels, family size, season and 
method of birth, geographical location, and the presence of pets in a household have also 
been cited as possible factors in the development of asthma and allergies.  Lower vitamin 
D levels have been shown to be associated with allergic disease and elevated serum IgE44 
as well as increased severity of atopic dermatitis in children with allergies.45  It has also 
been reported that mothers who took vitamin D during pregnancy had children with a 
reduced risk of wheeze and eczema.46  Researchers found that acute allergic reactions are 
more common in the northeastern part of the U.S. than in the Southern U.S., which has 
been hypothesized as being related to sun-exposure and vitamin D levels.47 Seasonal 
factors have also been investigated since many factors change over the course of a year—
time of sunlight per day, pollen levels, time spent indoors and exposure to indoor 
allergens.  Children born in autumn and winter have been shown to have a higher 





common foods like egg white, milk, and wheat.48  It has also been reported that children 
born by cesarean section are at an increased risk of asthma and atopy, which may be 
related to disruptions or delayed colonization of the infant’s gut with beneficial 
microbiota.49 
Exposure to more outdoor allergens may be important in preventing allergies.  
Children living in rural areas have a lower prevalence of food allergy than those living in 
urban centers (6.2% vs 9.8%).50 Children in rural areas also have other lifestyle 
differences such as greater number of siblings, less exposure to tobacco smoke, and are 
more likely to have pets or be exposed to animals, that could account for the decreased 
prevalence of atopy.51  A greater number of siblings and exposure to pets during the first 
year of life is associated with a lower prevalence of allergic rhinitis and asthma.52  It has 
also been proposed that children’s exposure to air pollutants, such as diesel particles, in 
urban centers can contribute to the development or worsening of allergies and asthma by 
inducing inflammatory responses.53,54 
Sensitization may also be related to blood transfusion, bone marrow, and organ 
transplants.  Blood transfusions can result in passive sensitization.  It has been shown that 
donor IgE antibodies can sensitize recipient’s mast cells and basophils within 3 hours 
after transfusion and that, in one blood collection center, 23% of blood donors had 
significant levels of IgE antibodies to common allergens.55  Peanut allergens have been 
shown to be passively transferred from a donor’s blood and have caused anaphylaxis in at 
least 1 recipient.  There has also been one instance where a patient developed a serious 
anaphylaxis nut allergy after receiving a liver transplant from a boy that had died from 





transferring allergies then other organ transplants due to the pluripotential hematopoietic 
stem cells and dendritic cells that reside in the liver.57  Food allergy transfers have also 
been reported in heart, lung, kidney, and intestinal transplants, and the allergy is more 
likely to transfer if the recipient is a child.58  Most of the transferred food allergies have 
been reported to resolve after a few years.58 
Peanut Exposure 
Exposure to allergens can be deadly for those children that do have severe food 
allergies.  Even small amounts of contamination have been shown to have serious 
effects.59 The Food Allergen Labeling and Consumer Protection Act (FALCPA) was 
implemented in 2004 in response to the growing danger of allergen contamination and 
exposure.  The act requires food manufacturers to indicate if a product has a major food 
allergen.  The act defines eight major food allergens: milk, eggs, fish, crustacean 
shellfish, tree nuts, peanuts, wheat, and soybeans.  These eight food allergens are said to 
account for over 90% of all documented food allergies in the United States.60   Food 
manufacturers have made great strides in labeling foods since the act went into effect in 
2006; however, the FDA has not established any threshold levels for any of the allergens.  
This has led to inconsistent labelling between companies.  Some companies put 
generalized contamination statements on food products such as “this product was 
produced in a facility that also process peanuts” even though the risk is extremely low, or 
they simply put every one of the eight major allergens so they have no liability concerns, 
whereas other companies with much higher chances of contamination will not add such 





“shared facility,” “shared equipment,” and “may contain.” This can be frustrating and 
confusing to those that have food allergies. 
The question of how much contamination is in the food is a real concern. The 
issue is further complicated by the fact that every allergic patient will have a different 
level at which they will react to the food antigen.  A study in 2007 tested 200 different 
food products with disclaimers and only detected clinically significant contamination in 
13 products.61 Another study found that peanut was only found in advisory label products 
7.3% of the time but 33% of the time when it was labeled as a minor ingredient.62 
Research has shown that consumers are increasingly ignoring food contamination 
disclaimers and from 2003 to 2006 the percentage of those heeding the warnings dropped 
by ten percent.61 
Ballmer-Weber et al recently did a study where they looked at what concentration 
level a food had to get to before it provoked a response in allergic patients. They then 
defined a threshold in which, theoretically, only 10% of allergic patients would have a 
reaction.  Peanut’s contamination cut-off level was defined as 0.03 mg.63 Their study 
lacked patients that had a history of anaphylaxis so it does not display a true reflection of 
the general population.  It does, however, provide a good starting point under which 
manufacturers should try to get their levels of contamination. 
Some have suggested that manufacturers could also test for contamination in the 
factories and put the level of contamination on their products (ie, “This product was 
produced in a facility that also processes peanuts.  Contamination levels may reach up to 
0.01 mg”).  Thus, every person would be able to evaluate whether or not they could 





different lab tests might use slightly different epitopes or kits and the results may not be 
standardized.  The second reason is that the antigenic epitopes can be altered by different 
cooking methods (ie, heating, baking).  It is also difficult to get consistent results with 
allergens when they are in different food matrixes.  It has been shown that fat content can 
alter the levels of peanut detected in ELISA-based assays and that allergic patients are 
able to ingest more peanut protein when they are in high fat recipes.64 
Methods of Diagnosis of Food Allergies 
 Double-Blind Placebo-Controlled Food Challenge (DBPCFC) 
The DBPCFC has been considered the gold standard in allergen testing for many 
decades.  The principle behind it is relatively simple.  The food suspected of causing a 
reaction is given to a patient in increasing doses to see if it does, in fact, cause a reaction.  
This inherently makes the DBPCFC a dangerous and unappealing test to patients. 
 There are several problems that have to be addressed when doing food 
challenges.  The first is that stress and anxiety can cause false positives so placebo doses 
must be mixed in with the true doses to make sure results are accurate. The second is that 
anti-histamines, other anti-allergy drugs, or immunosuppressive medications can interfere 
with the results and must be discontinued several days or weeks before the challenge.  
The third and most important problem is that when a reaction is provoked, it can quickly 
become life-threatening and medical personnel must be present at all times and ready to 
treat any reaction that occurs. 
The problems that have to be addressed when performing DBPCFCs make them 





specific food will have on a patient. 
Skin-Prick Testing (SPT) 
SPT techniques have been utilized since 1865.65  The technique is relatively 
simple, in which a small amount of allergen is placed in the skin through pricking or 
scratching the skin.  Histamine and saline solutions are used as controls.  Any wheals that 
develop after 15 minutes are indicative of sensitization and the larger the wheal the more 
likely that the patient has a true allergy. Three millimeters wheals and larger are generally 
considered positive for an allergy.  However, there are some differences between 
manufacturers and between single and multiheaded skin testing devices and it has been 
recommended that three millimeters is not arbitrarily used as a positive threshold.66 A 
skin prick result of greater than 8 millimeters has been shown to have a high predictive 
value for clinical allergy to peanut.67 
Multiple factors can affect SPT such as the location on the body, sun damage of 
the skin, allergen extract quality, and certain medicines such as antihistamines, 
antidepressants, and steriods.68  The repeatability of skin prick testing has been questioned 
and investigated by several researchers.   One study, done over the course of 3 years, 
found that a positive SPT had a repeatability of 100% when supported by a history of 
allergy; however, it drops to 67% when there was no history of allergy.69 A twenty-year 
study found that skin prick test positivity done at 5 years of age had a reproducibility of 
100% at 6 and 15 years later and did predict allergy symptoms; however, many new 
positive allergens did occur over that time span so its sensitivity was not high (23-28%).70  





account.  It has been shown that there can be significant interphysician variation on 
results that are not strongly positive or negative.71 
 Currently whole peanut extract derived from native peanut is most commonly 
used in allergy clinics.  It is also possible to do SPT testing with recombinant peanut 
components and it has been suggested that this may yield more consistent results.72 
Studies trying to correlate peanut component SPT with the severity of the peanut allergy 
have been performed.  It was found that when researchers did the SPTs at multiple 
concentrations the more severe patients had significantly higher SPT reactivity to Ara h 2 
and Ara h 6 at low concentrations,73 indicating that perhaps when diagnosing peanut 
allergy two or three different concentrations of allergens could be used to further evaluate 
the severity of the allergy.  
Blood Tests –RASTs & ImmunoCAP 
The first blood tests were radioallergosorbent tests (RASTs).  These tests detected 
a patient's IgE antibody level to a specific food by using purified food antigens and anti-
IgE antibodies that were bound to a radioactive isotope.  Later blood tests used the same 
principle but had an enzyme bound to the anti-IgE antibodies that create either a 
fluorescent or luminescent signal instead of a radioactive one. 
Blood tests have several advantages and disadvantages.  Their major advantage is 
that they are very convenient and easy for the patient.  There is also no risk of 
anaphylactic reactions and the test is unaffected by anti-allergy drugs so patients do not 
have to stop taking their medications.  One of the disadvantages is that antibodies can 





indicate sensitization to allergen and not whether the patient would actually react to the 
allergen.  Studies looking at the utility of IgE tests have, therefore, had to set somewhat 
high concentrations of antibodies to achieve good positive predictive values.  These cut-
off levels for 95% positive predictive value vary from 15 kU/L to 24.1 kU/L.67,74  It is 
also important to note that it is recommended that tests done with different methodologies 
not be compared even if they have the same units of measurements.68 
Basophil Activation Tests (BAT) 
BAT testing is a new type of testing that has not yet achieved widespread use in 
the allergy community.  BAT-allergy testing is based on the principle that if a person is 
allergic to something, they have specific IgE antibodies that circulate in the blood and 
that also bind to basophils and mast cells.  Then, when the bound antibodies encounter 
the antigen for which they are specific, they set off a cascade that leads to basophil 
degranulation.  Degranulation in turn leads to the expression of CD63 on the cell surface 
which can be quantified by flow cytometry.  BAT testing is further discussed in Chapter 
4. 
Treatments for Peanut Allergy 
The percentage of children that outgrow their peanut allergy tends to be lower 
than most other common food groups.  A small study done in 1989 originally reported no 
natural resolution in atopic individuals but they had a small population size (n=36).75   
More recent studies done with large populations have shown that approximately 21.5% 





allergy, there are several different treatment options available: avoidance diets, oral 
immunotherapy, subcutaneous immunotherapy, probiotic oral immunotherapy, and anti-
IgE therapy. 
Avoidance diets are actually the absence of treatment.  In these cases, the patient 
is usually told to avoid eating peanuts and all possible exposures to peanuts.  If the 
allergy is severe, they may also be given epinephrine shots (EpiPen’s) in case they do 
accidentally ingest peanuts and go into anaphylactic shock.  Avoidance diets do prevent 
adverse reactions, but they do not resolve the allergy. 
Sublingual immunotherapy (SLIT) and oral immunotherapy (OIT) are two 
approaches to desensitizing patients to allergens.  In SLIT, small amounts of allergen 
extract are placed under the tongue daily.  In OIT, the small amounts of allergens are 
swallowed and ingested daily. In one double-blind, placebo-controlled study, they found 
that children undergoing SLIT were able to safely ingest 20 times more peanut protein 
then the placebo group after 1 year of treatment.77  OIT studies have had similar results.78  
There are dangers to using SLIT and OIT, however, including the risk of anaphylaxis and 
life-threatening allergic reactions.  Most participants also report minor allergic reactions 
throughout the treatment process.79 
The long-term results of SLIT and OIT also need to be further evaluated.  One 
study found that 4 weeks after finishing peanut OIT only 50% of the patients were able to 
pass a food challenge.80  Another disadvantage of SLIT/OIT is that it does take months to 
years to complete the therapy and adherence to the daily doses can be poor.  One study 
found that over 50% of patients on a 3-year peanut SLIT discontinued therapy before 





Using probiotics to treat allergies is a recent innovative idea.  Immunological 
studies have shown that probiotic bacteria by-products like short chain fatty acids can 
increase extrathymic generation of T regulatory cells.82  One recent study done in 
Australia enrolled 62 children to undergo oral immunotherapy and then they gave half of 
the children the probiotics bacterium Lactobacillus rhamnosus to take alongside their 
scheduled peanut protein doses.  The other half of the enrolled children functioned as a 
placebo control group and they received no probiotics and placebo doses consisting of 
maltodextrin with brown food coloring and peanut essence. They found that 82.1% of the 
probiotics groups achieved sustained unresponsiveness after the treatments, whereas only 
3.6 % of the control group achieved sustained unresponsiveness.83  Even more surprising 
was that food challenges performed 2 to 5 weeks later after patients were put back on a 
peanut elimination diet showed that 23 out of 25 patients were still tolerant to peanut.  
The researchers are planning on doing further food challenges on a later date to determine 
how long lasting the tolerance is. 
It is important to note that while the probiotic immunotherapy research is 
promising, there are also dangers to using probiotics.  Four major probiotic metabolites 
(butyric acid, flagellin, lipoteichoic acid, propionic acid) that are currently being studied 
and have been shown to have health benefits have also been linked to a wide range of 
disease and conditions such as cancer, mental retardation, synergistic enhancement of 
endotoxins/inflammation, and long-term behavioral deficits.84  More research into 
mechanisms of how probiotics work and which strains are the safest still needs to be 
performed.  It has also been suggested that certain patients such as neonates or those with 





probiotic use have been reported.85  
Another important treatment option is Anti-IgE therapy with Xolair, also known 
as omalizumab.  It has been shown that the frequency of peanut-specific T cells is higher 
in those with peanut allergy and that IgE depletion decreases the proliferation of those 
cells.86 Xolair is an antibody that binds to a CH3 domain on IgE molecules and 
effectively neutralizes free IgE in the serum and is considered an effective therapy for 
food allergies, asthma, atopic dermatitis, and chronic urticaria.87  It has been shown to 
downregulate FcϵRI on mast cells and basophils to <5% within a few months of the start 
of treatment.88  Xolair is FDA-approved for adults and children starting at age 12.  It is 
injected under the skin every 2 to 4 weeks by a healthcare provider.  There are also some 
major risks to taking Xolair, including anaphylaxis, fever, muscle aches, rash, parasitic 
infections, and the more common side effects seen include pain in arms/legs, dizziness, 
nausea, headaches, cough, joint pain, and upper respiratory tract infections.89  The 
effectiveness of anti-IgE treatment can be monitored by measuring the amount of allergen 
needed to cause basophil activation, called CD-sens, which has been shown to correlate 
well with determining a patient sensitivity level as they undergo anti-IgE treatment.90  














Recruitment of Patients 
This research study was reviewed and approved by the University of Utah 
Institutional Review Board (IRB #84399: Basophil Activation in Allergic Disease.)  
Recruitment of patients was done at Primary Children's Hospital (PCH) in the pediatric 
allergy clinic over the course of several months.  All patients gave written informed 
consent or assent along with parental informed consent before entering the study. 
A total of 47 peanut-allergic patients were recruited from PCH.  All PCH patients 
had either positive SPT or detectable SIgE levels to peanut and all patients had varying 
levels of clinical allergy symptoms.  These patients all had SIgE levels and basophil 
activation testing performed on their blood.  A total of 7 atopic patients being seen for 
other allergies and conditions were also recruited from PCH during the same time period 
and were all clinically tolerant to peanut.  The median age for the two groups were 
comparable (6.5 years vs 8.3 years)(p=0.497).  The percentage of males/females for the 
PCH group was pretty evenly split with females accounting for 55% of the study 
population.  The control group had a lower percentage of female participants (0.29%) 
which has due, in part, to the group’s much smaller sample size and the randomness of 






females, this difference is not clinically relevant. 
The patients were put into five different groups based on their SPT results and 
clinical presentation.  Refer to Figure 2.1 for a flow diagram of the different groups.  
Group One was designated for patients that had previously diagnosed peanut allergies 
and had agreed to participate in a peanut challenge.  Group Two patients had positive 
SPT testing and at least one objective symptom after ingestion of peanut.  Group Three 




Positive SPT testing with 
Clinical Symptoms
Group 3:
Positive SPT testing with no 
known previous exposure to 
peanuts
Group 4:
Negative  or Not Available SPT 
testing  with Variable  Clinical 
Symptoms or no exposure to 
peanuts
Other Suspected Food 
Allergies
Clinically Tolerant to Peanut
Group 5:
Atopic Controls
No Clinical Symptoms to 
Peanuts.  Variable SPT results
Confirmed Peanut Allergy
Group 1: Patients Underwent 
Open Food Challenge





parental preference, other family members were allergic to peanuts, or they had a strong,  
confirmed tree nut allergy.  Group Four patients had either a negative SPT or an SPT that 
was not done due to a variety of reasons including risk of anaphylaxis. 
Experimental Design 
One extra EDTA tube was drawn at PCH in addition to tubes patients were having 
drawn for routine clinical tests.  The EDTA tube was then sent to ARUP where it was 
prepared for BAT testing.  The optimal testing time was to have samples prepared and 
analyzed within 9.5 hours of the collection time.  This was achieved in 94.5 % of patient 
samples.  Following completion of the BAT testing, samples were spun down at 1500 
rpm for 7 minutes and the plasma was then removed and stored at -20˚C in case further 
serological testing was needed. In most cases, the IgE testing was ordered by the 
physician as part of the patient’s clinical labs and in cases where it was not serology 
testing was done after BAT was completed.  The background and methodology of the 
















SPECIFIC IMMUNOGLOBULIN E PATTERNS  
TO PEANUT COMPONENTS 
Introduction to Immunoglobulin E Utility 
 There are five different classes of immunoglobulins: G, A, M, D, and E. The 
Immunoglobulin E (IgE) class was discovered in 1967 and was formally recognized by 
the World Health Organization International Reference Centre in 1968.  It usually has the 
lowest concentration in the blood and has a shorter half-life then all of the other 
immunoglobulins.91 
 IgE is produced when the body identifies a foreign antigen such as a food or a 
helminth and correspondingly the levels of IgE are elevated in allergies and parasitical 
infections. The early IgE response is mounted in extrafollicular sources and is of low 
affinity.  Affinity maturation and progression to the germinal center results in higher 
affinity IgE followed by the generation of long-lived plasma cells that sustain the IgE 
response.91 
 IgE can be found circulating in the blood or bound onto the surface of cells. The 
IgE molecules are bound onto cells via a cell receptor that bind to the Fc region of the 
antibody. These receptors are denoted as FcϵR and there are several different classes.  






and basophils. Class II (FcϵRII) are low affinity receptors that are seen on B-cells, 
monocyte, and dendritic cells; however, their role in allergies is still being investigated.92  
Conventional blood tests measure the free serum IgE level.  It has been shown that the 
serum IgE level correlates well with cell-bound IgE in most patients.93 
 It has been shown that the more IgE epitopes that a person recognizes for a specific 
antigen the more sensitive they are to that antigen.94 
Materials and Methods 
 All specific IgE levels were determined on an ImmunoCAP1000 instrument 
(ThermoFisher Scientific/Phadia) using fluorescent enzymatic immunoassay 
methodology.  Appropriate positive and negative manufacturer controls were run 
alongside patients. SIgE levels were quantified down to the 0.10 kU/l level and up to the 
100 kU/l level.  SIgE levels of ≥0.10 kU/l were considered positive for the whole 
peanut and for the purified peanut components. 
Correlation of Component Testing 
 The correlation and reliability between whole peanut and its components on the 
ImmunoCAP testing platform was evaluated before the study began.  SIgE data from 
2,000 previous tested samples from suspected peanut-allergic patients from October 2014 
to July 2015 were pulled and analyzed. Of the 2,000 results, 239 (11.95%) proved to be 
negative to both whole peanut and the components and were excluded from calculations.  
The remaining samples were then classified as to which tests were positive.  Thirty-





patterns are shown in Table 3.1 along with the observed number of events with 
monosensitization patterns highlighted in light blue and di-sensitization patterns in a 
darker blue. 
Two different types of inconclusive results were noted: whole peanut inconclusive 
(WPI) and peanut component inconclusive (PCI). WPI was classified as results where 
there was detectable whole peanut antibody levels, but all of the tested components had 
undetectable levels.  This occurred in 146 (8.29%) of samples and the range of results 
varied from 0.10-9.76 kU/L. These samples could be sensitized to some of the untested 
peanut components, such as Ara h 5, 6, 7, 10-13, that have not been studied as thoroughly 
and are not commercially available. It is also possible that these samples are false 
positives due to cross-reactivity or lab error; however, a European study published last 
year did note WPI in their study and that 7 patients out of their 68 patient population 
(10.3%) had detectable peanut SIgE but no IgE to Ara h 1, Ara h 2, Ara h 3, Ara h 6, Ara 
h 8, and Ara h 9 which is similar to what was seen with our analyzed test results.24 
PCI was classified as results where any one of the components was positive but 
the whole peanut extract was negative.  These were of special interest as clinicians that 
only ordered whole peanut SIgE testing could miss these cases of sensitization.  PCI 
occurred in 18 (1.04%) of samples with Ara h2 being the most often seen (n = 8), 
followed by Ara h 2 and 9 (n = 3, each), and then Ara h 1 and 3 (n = 2, each). The range 
of results varied depending on the component; they are shown in Table 3.2.  Most of the 
PCI cases had rather low values of sensitization; however, there was one concerning case 
(# 1021) that had a Ara h 2 value of 0.39 and no detectable response to whole peanut.  As 
















# of Pt 
w/>100 
Results 
% of Pt 
w/>100 
Results Observed Pattern 
1 Peanut h1          h1 only 28 1.59% 0 0.00% 
2 Peanut  h1 h2        h1,h2 143 8.12% 1 0.70% 
3 Peanut h1 h2 h3      h1,h2,h3 346 19.65% 109 31.50% 
4 Peanut  h1 h2 h3 h8    h1,h2,h3,h8 98 5.57% 38 38.78% 
5 Peanut  h1 h2 h3 h8 h9  h1,h2,h3,h8,h9 164 9.31% 66 40.24% 
6 Peanut  h1 h2 h3   h9  h1,h2,h3,h9 106 6.02% 32 30.19% 
7 Peanut  h1 h2   h8    h1,h2,h8 19 1.08% 0 0.00% 
8 Peanut  h1 h2   h8 h9  h1,h2,h8,h9 6 0.34% 0 0.00% 
9 Peanut  h1 h2     h9  h1,h2,h9 19 1.08% 0 0.00% 
10 Peanut  h1   h3      h1,h3 21 1.19% 0 0.00% 
11 Peanut  h1   h3 h8    h1,h3,h8 3 0.17% 0 0.00% 
12 Peanut  h1   h3 h8 h9  h1,h3,h8,h9 5 0.28% 0 0.00% 
13 Peanut  h1   h3   h9  h1,h3,h9 18 1.02% 0 0.00% 
14 Peanut  h1     h8    h1,h8 1 0.06% 0 0.00% 
15 Peanut  h1     h8 h9  h1,h8,h9 1 0.06% 0 0.00% 
16 Peanut  h1       h9  h1,h9 1 0.06% 0 0.00% 
17 Peanut   h2        h2 only 264 14.99% 0 0.00% 
18 Peanut   h2 h3      h2,h3 34 1.93% 0 0.00% 
19 Peanut   h2 h3 h8    h2,h3,h8 13 0.74% 0 0.00% 
20 Peanut   h2 h3 h8 h9  h2,h3,h8,h9 9 0.51% 0 0.00% 
21 Peanut   h2 h3   h9  h2,h3,h9 15 0.85% 0 0.00% 
22 Peanut   h2   h8    h2,h8 56 3.18% 0 0.00% 
23 Peanut   h2   h8 h9  h2,h8,h9 20 1.14% 1 5.00% 
24 Peanut   h2     h9  h2,h9 37 2.10% 0 0.00% 
25 Peanut     h3      h3 only 27 1.53% 0 0.00% 
26 Peanut     h3 h8    h3,h8 5 0.28% 0 0.00% 
27 Peanut     h3 h8 h9  h3,h8,h9 2 0.11% 0 0.00% 
28 Peanut     h3   h9  h3,h9 12 0.68% 0 0.00% 
29 Peanut       h8    h8 only 64 3.63% 1 1.56% 
30 Peanut       h8 h9  h8,h9 17 0.97% 0 0.00% 
31 Peanut         h9  h9 only 43 2.44% 0 0.00% 
32    h1          Inconclusive h1 2 0.11% 0 0.00% 
33     h2        Inconclusive h2 3 0.17% 0 0.00% 
34        h3      Inconclusive h3 2 0.11% 0 0.00% 
35         h8    Inconclusive h8 8 0.45% 0 0.00% 
36 
          h9 
 Inconclusive h9 3 0.17% 0 0.00% 
37 
Peanut 





Table 3.2 Peanut Component Inconclusive Results 
 ID # Peanut Ara h 1 Ara h 2 Ara h 3 Ara h 8 Ara h 9 
176 <0.10 0.11 <0.10 <0.10 <0.10 <0.10 
465 <0.10 0.12 <0.10 <0.10 <0.10 <0.10 
368 <0.10 <0.10 0.11 <0.10 <0.10 <0.10 
1021 <0.10 <0.10 0.39 <0.10 <0.10 <0.10 
1596 <0.10 <0.10 0.10 <0.10 <0.10 <0.10 
347 <0.10 <0.10 <0.10 0.15 <0.10 <0.10 
694 <0.10 <0.10 <0.10 0.17 <0.10 <0.10 
231 <0.10 <0.10 <0.10 <0.10 0.40 <0.10 
235 <0.10 <0.10 <0.10 <0.10 0.22 <0.10 
591 <0.10 <0.10 <0.10 <0.10 0.47 <0.10 
617 <0.10 <0.10 <0.10 <0.10 0.46 <0.10 
949 <0.10 <0.10 <0.10 <0.10 0.19 <0.10 
1158 <0.10 <0.10 <0.10 <0.10 1.06 <0.10 
1482 <0.10 <0.10 <0.10 <0.10 0.16 <0.10 
1687 <0.10 <0.10 <0.10 <0.10 1.40 <0.10 
166 <0.10 <0.10 <0.10 <0.10 <0.10 0.19 
1072 <0.10 <0.10 <0.10 <0.10 <0.10 0.39 
1384 <0.10 <0.10 <0.10 <0.10 <0.10 0.16 
 
specificity of 96% and a sensitivity of 100%.15  The high number of Ara h 8 PCI may be 
due to its low content in whole peanut extract. 
SIgE Sensitization Patterns 
Overall, monosensitization was seen in 24.24% of the cases with Ara h 2 being 
the most common (15.05%) followed by Ara h 8 (3.63%), Ara h 9 (2.44%), Ara h 1 
(1.59%), and Ara h 3(1.53%).  This differs somewhat from the literature in that most 
literature has reported monosensitization as a rarer event.  
Ara h 8 monosensitization has been reported with occurrence rates of 3.3%, 
11.4%, 12.0%, and 17.6 % in true peanut-allergy populations in United States, Sweden, 





monosensitization is also well documented among peanut-tolerant patient populations.24  
Ara h 2 monosensitization (6.7%, 8.6%, 4.6%, 4.1%) was also noted by those same 
researchers in peanut allergic patients, but they were usually at lower rate than the Ara h 
8 monosensitization.   
 Ara h 9 was noted in only two of the twelve studies.  One had an extremely low 
rate of 1.4%, whereas the other study reported a rate of 36%; however, the second study 
population was in Spain where Ara h 9 sensitization has been reported to be higher.20,95  
Ara h 1 monosensitization was likewise reported in only two out of the twelve studies 
with rates of 3.3% and 6.0%.95 
It is important to note that the different studies did use slightly different cut-off 
values for establishing positivity.  Traditionally, 0.35 kU/l has been used as the cut-off 
for determining allergy for any food but since the advent of highly purified components 
and given the severity of peanut allergies any detectable level (>0.10kU/l) of antibodies is 
now being labeled as positive in most instances.   
We also used our data to evaluate the correlations and patterns between the 
different component tests.  Most literature has reported that positive results to Ara h 6 
almost always occurs with a positive Ara h 2 level and that a similar relationship is seen 
with Ara h 1 and Ara h 2 and then Ara h 3 and Ara h 2.96 
A statistical analysis was done on the 1,761 results with detectable IgE antibody 
present and scatter plots were done that show the relationship between peanut and the 
different tests and then between the tests themselves.  Values of <0.10 were entered in as 
0.09 and values of >100 were entered in as 101.  Figure 3.1 shows the different scatter 





plots between the component tests.  Ara h 2 correlated the best with the whole peanut 
result (r = 0.92), which matches what is seen in the literature.  The worst correlations 
were seen with Ara h 8 and Ara h 9 (r = 0.04 to 0.11) which also matches the literature 
and is attributed to cross-reactivity to Bet v2 and lipid transfer proteins. Table 3.3 shows 
the correlation coefficients for the each of the SIgE test in relation to the other tests.  The 
best correlations among the component comparisons were with Ara h 1 to Ara h 3 and h2.  
The correlation coefficients were fairly high, r = 0.81 and 0.70, for Ara h 1 compared to 
Ara h 2 and Ara h 3.  Ara h 3 did not correlate very well with Ara h 2, r = 0.59.  The 
analysis did show, however, that matched sensitization between Ara h 1 and Ara h 2 
occurred in 92.0% of Ara h 1 sensitizations, Ara h 3sensitization occurred in 77% of 
cases of Ara h 1 sensitization, and Ara h 2 was present in 89.4% of cases of Ara h 3 
sensitization.  So although the levels of antigen did not correlate, the positivity (defined 


















Table 3.3 Correlation between SIgE Tests 
 Peanut Ara h 1 Ara h2 Ara h 3 Ara h 8 Ara h 9 
Peanut 1.00 --- --- --- --- --- 
Ara h 1 0.80 1.00 --- --- --- --- 
Ara h 2 0.92 0.81 1.00 --- --- --- 
Ara h 3 0.55 0.70 0.59 1.00 --- --- 
Ara h 8 0.11 0.05 0.04 0.06 1.00 --- 











BASOPHIL ACTIVATION TESTING TO 
DETERMINE TRUE ALLERGY 
Introduction 
There are two types of Basophil Activation Testing (BAT).  The first is the 
simplest and is where a patient’s blood is drawn and the whole blood sample is 
stimulated with antigen. Then, after a red blood cell lysing step, the sample is placed on a 
flow cytometer and gated for basophils.  The second method, called passive sensitization, 
is where a donor provides basophils which are then stripped of all of their surface 
antibodies. Then patient serum is added to the stripped basophils to “reload” the surface 
with antibodies. The suspected antigen can then be added to see if degranulation occurs.  
Both methods have advantages and disadvantages.  The first method is limited by the 
need for fresh whole blood which means samples cannot be frozen and has a preferred 
testing window of less than 24 hours.  The second method that involves basophil-
stripping eliminates the need for fresh patient whole blood and can use patient serum 
which can be frozen and is stable for weeks or months depending on the storage 
temperature.  However, the second method is much harder to standardize.  Different 






the basophils are not activated while they are being stripped. This has led to interest in 
creating cell lines that contain the FcεRI receptor and could be loaded with patient IgE 
and therefore be more standardized and reliable then donor basophils. 
Unfortunately many obstacles still need to be overcome.  For cell lines that are 
not of human origin, like rat basophilic leukemia cell lines (RBL), human FcεRI 
receptors must be transfected into the cells.  One study evaluated three different RBL cell 
lines and found that all of these transfected humanized cell lines had a high percentage of 
IgE binding to the FcεRI receptors; however, they had inconsistent degranulation when 
an allergen was introduced and they had loss of the expression of the human FcεRI 
receptors after prolonged culture.97  It is important to note that the inconsistent 
degranulation may be due to several different factors.  The first is that there can be many 
other specificities of the IgE antibodies present in a patient’s serum.  For example, more 
anti-dog, anti-pollen, or nonspecific antibodies might end up binding to the FcεRI 
receptors instead of the antibody of interest.  The second is that when using transfected 
cell lines, there is a variable number of FcεRI receptors that are expressed on the cell 
surface.  The number of receptors on the cell line may also not match the number of 
receptors on the patient’s basophil; therefore, the cells lines may have decreased or 
increased sensitivity.  
  It is also important to avoid contamination with aeroallergens and occupational 
allergens that can be found in the clinical lab.  Contamination from latex gloves or 
airborne contaminants, like molds or pollen, can cause false positives or it can modify the 
results in cases where a patient is truly allergic to the allergen of interest.  It has been 





degranulation response while at higher allergen concentrations a second allergen 
decreases the response.98 
Cellular Flow Markers 
Several different flow cytometry markers and parameters can be used in BAT 
testing, including CCR3, SSC, CD63, CD213, HLA-DR, CD203, anti-IgE, anti-FCεRI, 
and fMLP.  
CCR3, CD123, HLA-DR, IgE, and SSC are used to identify the basophil 
population. CCR3 (eotaxin receptor) is expressed on both basophils and eosinophils.  It 
has been shown to be a stable and well expressed marker of basophils.99 A slight decrease 
in CCR3 expression upon basophil activation has been noted. Some studies noted a 40% 
gMFI reduction in CCR3 expression and that it displayed adequate sensitivity but weak 
specificity when used as a basophil activation marker.100 Hausmann et al evaluated this 
decreased expression in terms of BAT testing and found that the relative number of 
acquired stimulated basophils did not reach statistical significance and that it was the 
most consistent marker in all of their research donors.99  It is important to note that CCR3 
is not lineage specific and can be expressed on other cells so secondary parameters must 
be used in conjunction with it. 
CD123 is an interleukin 3 receptor and can be found on many subsets in the 
peripheral blood including basophils, eosinophils, monocytes, and dendritic cells. It can 
be used along with HLA-DR to select for basophils (CD123high/HLA-DRneg).  It has been 
shown that the CD123 and HLA-DR levels do not significantly change with basophil 





the more commonly used CCR3 and inflammation can cause HLA-DR expression to 
change.99 
IgE is problematic as a basophil identification marker.  Although basophils do 
have bound IgE molecules on their surface, there is great variation between individuals 
which is dependent on their IgE plasma levels.  In certain donors, up to 80% of cells in 
the basophil gating parameters would be misidentified if anti-IgE markers were used.99 
CD63 is also known as the lysosome-associated membrane protein-3, and as 
previously mentioned, it is an activation marker that is widely used in BAT testing either 
by itself or in conjunction with CD203. CD63 has an extremely low expression rate on 
resting basophils and therefore has high specificity for basophil activation.102  CD63 
upregulation occurs within a minute after stimulation with antigen and optimal 
expression of the marker occurs after 15-30 minutes.101  CD63 expression has also been 
linked more closely to anaphylactic degranulation, fast morphological changes, and 
release of intracellular granules than other markers like CD203.102  It has also been noted 
that CD63 has a bimodal expression with dim and bright expression on basophils,101,102 
but the clinical significance of this bimodal expression has yet to be investigated. 
CD203, also known as ecto-nucleotide pyrophosphatase phosphodiesterase-3, can also be 
used as a marker of activation because its levels are upregulated on degranulated 
basophils by several factors.  When using fMLP or anti-IgE controls, the upregulated 
tends to increase by a factor of 2-3.101  Since CD203 is present on resting basophils, 
however, researchers must be careful when using it and its upregulation is not as 





Materials and Methods 
For this research study, we used the FlowCAST kit manufactured by Buhlmann 
Laboratories. The manufacturer's recommended protocol was used and the whole peanut 
extract, Ara h 1, and Ara h 2 allergens were also obtained from the manufacturer.  
Recombinant Ara h 8 antigen (RP-AH8-1) was obtained from Indoor Biotechnologies 
and was run using the same protocol as the whole peanut extract.  Fifty microliters of 
patient whole blood was added to 100ul of a stimulation buffer that contained IL-3 to 
help prime the basophils and calcium to replace the calcium that was bound by 
EDTA. Fifty microliters of the peanut antigen was also added to each tube.  Three 
different concentrations were examined at for each allergen resulting in a dose-response 
curve.  Whole peanut and Ara h 8 antigens were performed at 100ng/ml, 20ng/ml and 4 
ng/ml.  Then as per the manufacturer, Ara h 1 was run at 1000ng/ml, 200ng/ml, and 40 
ng/ml and Ara h 2 was run at 200ng/ml, 40ng/ml, and 0.8ng/ml. Twenty microliters of 
anti-CD63-FITC and anti-CCR33-PE mouse antibodies, used to identify the basophils 
and the % of activation, were added followed by a 15-minute incubation in a 37˚C water 
bath.  After incubation, 2 milliliters of lysing reagent was used to remove RBC's and a 
quick wash step was used to remove cell debri.  The remaining cells were then run on a 
BD Canto flow cytometer.  A total of fifteen flow assays were performed on each patient: 
a background/negative control, two positive controls, three concentrations of whole 
peanut antigen, three concentrations of Ara h 1, three concentrations of Ara h 2, and three 
concentrations of Ara h 8. 
The background/control contained only stimulation buffer. A base value of less 





negative control by the kit manufacturer.  There were two positive controls that were 
defined as acceptable if one control caused >10% of basophils to upregulate CD63.  The 
first positive control that was used was anti-FcϵRI mouse antibodies that causes cross-
linking of surface-bound IgE antibodies similar to the allergen. The second positive 
control was a formyl-methionyl-leucyl-phenylalanine (fMLP) peptide which is produced 
during bacterial growth. The fMLP causes basophil activation by binding to cell surface 
receptors that act through G proteins and phospholipase C.  It has been used as a stimulus 
for neutrophil, monocyte, and basophil activation. 
Basophils were defined as the CCR3pos/SSClow population.  The percentage 
of basophils that displayed CD63 was calculated.  Positive allergic responses were 
defined as ≥10% upregulation of CD63.  See Figure 4.1 for a typical gating strategy on a 
patient. A total of 500-600 basophils was the preferred range for analysis and this was 
achieved in the majority of results (82%) and analysis of the background test for each 
patient showed the mean basophil recovery was approximately 558.  As per the 
manufacturer, patients with less than 200 basophils recovered were not eligible for 
analysis.  No patient results had to be excluded from this study due to low recovery. 
We attempted to include all of the tested SIgE peanut components in the BAT 
testing; however, Ara h 3 and Ara h 9 were not commercially available.  
Nonresponders and Signal Transduction 
One major drawback of BAT is that a significant proportion of the population 
have basophils that do not respond to stimulation with anti-IgE or anti-FcϵRI. These 














                





11.5-22%.103,104,105  Nonresponsive basophils do not appear to have any mutations or 
structural changes in their FcϵRI.106  In addition, they have similar cellular densities of 
IgE antibody as responsive basophils and can be activated by other non-IgE pathway 
through the use of different reagents such as fMLP, calcium ionophore A23187, and 12-
0-tetradecanoyl phorbol-13 acetate.105  It is currently believed that nonresponding 
basophils have issues with components in the intracellular signal transduction pathway. It 
has been shown that nonresponding basophils have hardly any changes in cytosolic free 
Ca2+ after the addition of anti-IgE and when given a second challenge with a non-IgE 
stimulus the response is inhibited, which is indicative that intracellular signals were 
generated but there was a problem somewhere in the signal cascade.107 
The initial cross-linking and activation of the FcϵRI receptors leads to the 
activation of Lyn, a protein tyrosine kinase, which in turn phosphorylates the 
immunoreceptor tyrosine-based activation motifs on the β and γ subunits of the receptor 
and then Syk is recruited and activated. Eventually, the cascade leads to the creation of 
second messengers, IP3 and 1,2-diacylglycerol in particular, that cause the release of 
Ca2+ and start to trigger the release of basophilic granules and histamine.  
 It has been shown that two regions in the IgE-mediated signal transduction 
pathway are downregulated during stimulation: one that controls the protein kinase Syk’s 
phosphorylation, and one that controls the PI3 Kinase.108  The Syk kinase in particular 
has been shown to decrease by 20% after a 1-hour stimulation and an 80% decrease in 
incubations >18 hours.109  This appears to be due to ubiquitination of syk by c-cbl, which 
is originally phosphorylated and activated by syk, lyn or fyn, and it has been suggested 





also looked at in a small study that took purified nonresponding basophils from 3 
different donors and performed Western blots to look at the levels of syk and lyn. It was 
found that the basophils failed to express syk and had normal to reduced levels of Lyn.110 
 Interleukin 3 (IL-3) has been shown to restore the signaling function of non-
responding basophils.106  A 3-day incubation period with IL3, however, is needed to 
restore functionality.  This makes the use of IL-3 in clinical testing problematic and calls 
into question how the results would correlate in vivo.  A short 15-minute incubation with 
IL-3 buffer was used in our assay, but its main function was to help prime basophils and 
not address the nonresponder issue.  It has been shown that IL-3 can increase the 
sensitivity of basophils when in the presence of certain antigens and can help provide a 
better distinction between antigen-stimulation activation and unspecific activation.102 
Basophil Allergen Thresholds: CD-sens and CD-max 
CD-sens is defined as the allergen concentration that causes 50% of basophils to 
activate and upregulate CD63 and it is measured by inverting the allergen concentration 
and multiplying by 100.55  CD-max is defined as the maximal percentage of CD63 
upregulation at any one allergen dose90 which can vary from person to person, in part, 
due to the variability of bound IgE which is necessary to form crosslinking.  CD-sens has 
been shown to be a better measure of allergen sensitivity then CD-max.90  It has also been 
used in conjunction with food challenges and it has been found that 92% of children that 
fail a food challenge have positive CD-sens.111 
The optimal cut-off concentration for discriminating between peanut-allergic and 





peanut was used as our highest concentration in this study, which was in line with 
manufacturer recommendations. The manufacturer also recommended testing four other 
concentrations, but we only did two additional concentrations since the aim of our study 
was to correctly diagnose peanut allergies rather than monitor desensitization therapies. 
The three concentrations do allow us to get a sense of the severity of the allergen and 
provide a CD-sens in all but the extremely sensitive peanut allergy patients that react at 


























PCH Patient Results 
Fifty-four total patients were recruited from PCH; however, 13 patients had to be 
excluded from the analysis.  Nine patients (16.6%) were determined to be non-
responders, 8 patients from the peanut allergy group and 1 from the atopic controls.  Four 
patients also had to be excluded due to high backgrounds.  At least 3 of these high 
background patients were linked to a newly opened bottle of anti-CD63 reagent that was 
suspected of having bacterial contamination.  This left us with a total of 35 peanut allergy 
patients and 6 controls. 
SIgE positivity in the peanut allergy patients was 94.3% to whole peanut extract, 
54.3% to Ara h 1, 68.6% to Ara h2, 54.3% to Ara h 3, 17.1% to Ara h 8, and 14.3% to 
Ara h 9.  Monosensitization to a single component was seen to Ara h 2 (14%), Ara h 3 
(8.5%), and 1 patient who had Ara h 8 monosensitization and, after a peanut challenge, 
was proven to be tolerant to peanut. 
The PCH patients were originally divided into five groups, as was outlined in the 
Patient Recruitment section, based off of skin prick testing (SPT) results and clinical 






previously diagnosed with peanut allergy and had consented to undergo a food challenge.  
There were 3 patients in this group. Two out of the 3 had detectable SIgE levels to peanut 
(>100, 0.22 kU/l) and the third was monosensensitized to Ara h 8 (0.41 kU/l).  They all 
had convincing clinical histories of peanut allergies.  The BAT results in these cases did 
predict the outcome of the food challenge.   
The first patient was a 19-year-old female that had an IgE serum level of 
>100kU/L to whole peanut, Ara h 1, and Ara h 2.  She had been undergoing treatment 
with Xolair and her peanut SPT results had decreased from 38 to 13 to 0.  The BAT 
results showed no reactivity at the lowest concentrations of allergen, but there was 
basophil activation at the higher concentrations for all three allergens: 100ng/ml peanut = 
60.7% activation, 20ng/ml = 14.8% activation, 1000ng/ml Ara h 1 = 17.5% activation, 20 
ng/ml Ara h 2 = 51.3% activation, 4ng/ml = 14.7% activation.  The patient was able to 
tolerate 4mg of peanut protein before hives developed and the oral challenge was ended. 
She was put on an OIT regimen for several days but developed severe abdominal pain 
and that too was discontinued. 
In the two other food challenges, the BAT results for all the tested allergens were 
negative (<10% activation) and there was only a minor sensitization to Ara h 3 (0.13 
kU/l) in one of the patients.  The Ara h 8 monosensitized patient in Group 1 was unique 
and the tolerant status of the patient matches the current literature of Ara h 8 positive 
patients having more mild or negligible symptoms.  Studies using Ara h 8 in BATs were 
looked for when we started this project as there were none published; however, one paper 
published during our project that looked at basophil threshold sensitivity’s in 





varying concentrations (1.2-82.8 ng/ml).112  This study seems to suggest that Ara h 8 
might be still be an important allergen in these monosensitized populations.  
Unfortunately, we only had the 1 tolerant Ara h 8 monosensitized patient so we could not 
evaluate the importance of Ara h 8 in a true monosensitized allergic patient population. 
We did have 7 patients with detectable IgE to Ara h 8, 6 patients in the peanut allergy 
group and 1 patient in the control group.  The median value of Ara h 8 in the peanut 
allergy group was 0.97 kU/l and the range was 0.28-2.36 kU/l.  In all cases, the patient 
basophils did not react to the Ara h 8 antigens and they all had varying degrees of 
sensitization to Ara h 1, Ara h 2, and Ara h 3, so it is possible Ara h 8 is not as important 
in patients with multiple peanut component sensitizations.  There are also two isoforms of 
Ara h 8: 8.0101 and 8.0201.33  We only used 8.0101 in our research study.  The 
previously mentioned study did not note which isoform they used so it is also possible 
there might be a difference between the isoforms. 
The different PCH groups were evaluated to see if there was a difference in the 
nonresponder rate, total IgE, individual SIgE levels, and BAT upregulation at the highest 
concentration of each of the allergens.  The information is summarized in Table 5.1 and 
Figure 5.1 illustrates the mean difference in BAT upregulation for the whole peanut 
antigen and displays calculated p-values (t-test).   The rate of nonresponders was found to 
be pretty evenly distributed with 1 to 3 nonresponders occurring in each group.  The 
mean total IgE was generally around 300kU/l though it was a little higher in Group 4 
(582.1 kU/l), this group had a ‘not available’ SPT which occurred frequently when the 
patient had extremely high levels of SIgE and had known anaphylaxis to peanut such that 





Table 5.1 PCH Patient Results by Group 

















# of Patients 
 
4 19 10 11 7 
# of Non-responders 1 2 2 3 1 
Mean TIgE (kU/L) 337.9 340.4 258.1 582.1 368.7 
      Ranges (9.62-900) (6.7-1271) (59-697) (12-1613) (22-1899) 
Whole Peanut     
Mean SIgE (kU/L) 
 
33.7 23.2 12.8 36.3 3.6 
     Ranges (0-101) (0.10-101) (0.57-45.2) (0-101) (0-21.7) 
Mean BAT % 20.7 29.3 36.9 40.8 0.45 
      Ranges (0.2-60.7) (0-91.2) (0.2-84.2) (0.2-90.5) (0-1.5) 
Ara h 1     
Mean SIgE (kU/L) 
 
33.7 11.4 2.0 24.9 0.05 
Ranges (0-101) (0-73.7) (0-9.22) (0-101) (0-0.31) 
Mean BAT % 6.3 22.3 26.1 30.4 0.38 
Ranges (0.2-17.5) (0-87.7) (0.5-70.3) (0.2-93.8) (0.2-0.9) 
Ara h 2     
Mean SIgE (kU/L) 33.7 17.3 8.14 32.4 0.01 
      Ranges (0-101) (0-101) (0-23.1) (0-101) (0-0.04) 
Mean BAT % 17.6 22.2 32.9 34.6 0.12 
      Ranges (0.2-51.3) (0-88.4) (0.1-71.8) (0-87) (0-0.7) 
Ara h 8     
Mean SIgE (kU/L) 0.14 0.10 0.30 0.20 0.21 
      Ranges (0-0.41) (0-1.23) (0-2.36) (0-1.1) (0-1.26) 
Mean BAT % 0.50 0.66 0.55 0.65 0.52 
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Peanut BAT by SPT Grouping & Clinical Symptoms





particular, Group 3 patients who had never been exposed to peanut tended to have 
slightly lower SIgE levels than the rest of the peanut allergy groups.  There was not a 
statistically significant difference in the BAT between the individual groups (p=0.43-
0.83); however, in comparison to the controls, all groups except for Group 1 (Food 
Challenges) had statistically significant with p values ranging from 0.02 to 0.04. 
We originally placed the patients into groups by using SPT and the presence of 
exposure and clinical symptoms in hopes of finding a testing algorithm and patient 
population that would greatly benefit from BAT testing.  This, unfortunately, did not 
occur with this grouping scheme.  One possible reason for this may be the heterogeneity 
of the allergy population and the different reasons for the same outcome and grouping, ie, 
a 2-year-old child whose mother never exposed them to peanut for fear of them 
developing an allergy and tests mildly positive would end up in the same group as a child 
that has anaphylaxis to tree nut and positive peanut SPT and is told by a physician to 
never be exposed to peanuts.  Or in the case of SPT testing, large differences can be seen 
where one child will not have testing done because they have already had a documented 
anaphylaxis reaction versus another who perhaps will not behave long enough for SPT 
testing to be completed. 
Since the original grouping system proved ineffectual, a new category evaluating 
severity was added for each patient and the patients were then reclassified based on their 
clinical presentation.  Each patient was evaluated by a physician that had been blinded to 
the BAT results.  In general, mild cases were defined as patients with cutaneous 
symptoms such as hives, swelling, redness, and itching.  Moderate cases were defined as 





cutaneous symptoms.  Severe cases were defined as patients with symptoms of 
anaphylaxis and respiratory distress that required the use of epinephrine and 
hospitalization.  Then, there were also two categories for those never exposed to peanut 
and for those who had peanut allergy but then became tolerant to peanut.  The second 
analysis using these severity categories is summarized in Table 5.2 and illustrated in 
Figure 5.2 and Figure 5.3. 
Using severity of symptoms, instead of SPT and the presence or absence of 
symptoms, showed a much clearer picture of peanut allergies.  The total IgE increases 
steadily among the groups from 53.8, 321.4, 675, to 829 in the tolerant, mild, moderate, 
and severe groups, respectively. 
The difference between the severity groups themselves were, in general, not 
statistically significant (p = 0.21 – 0.50)(t-test); however, comparison between the severe 
and mild symptom groups was significant with a p value of 0.04.  Which is a very 
important discovery as it implies that it may be possible to discriminate between severe 
and mild peanut allergies using BAT without exposing children to peanut and risking 
allergic reactions.  There were several statistically significant results when comparing the 
severity groups to the negative controls.  The severe, moderate, and mild symptom 
groups had a p value of 0.0007, 0.04, and 0.03, respectively.  The tolerant and not 
exposed symptom groups did not achieve statistically significance (p = 0.61 and 0.06); 
this may be due to the lower numbers of patients in the tolerant group (n = 2) and the 
mixed population in the ‘not exposed’ group where allergy status is somewhat 
questionable since they have never been exposed to peanut. 








Table 5.2 PCH Patient Results by Severity 
 Not 
Exposed 




11 2 13 4 5 6 
Mean TIgE 
(kU/L) 
185.9 56.8 321.4 675 829 368.7 





63.8 9.5 71.8 60.3 66 81.7 
      ange 22.24-
88.7 
34.7-44.3 21.2-92.4 16.8-94.8 10.7-87 63.3-89.3 
Whole Peanut      
Mean SIgE 
(kU/l) 
9.2 0.11 19.5 75.9 41.6 3.6 
      Range 0.12-45.2 0-0.22 0->100 0.63->100 4.38-
>100 
0-21.7 
Mean BAT  28.4 0.07 28.1 40.7 62.2 0.45 
Range 0.2-84.2 0.2-1.2 0-91.2 0.3-90.5 13.8-90 0-1.5 
Ara h 1      
Mean SIgE  1.13 0.05 10.8 58.8 22.4 0.05 
Range 0-9.22 0-0.09 0-73.7 0.05->100 0-57.9 0-0.31 
Mean BAT 19.3 0.7 17.0 35.1 50.6 0.38 
Range 0.2-70.3 0.2-1.2 0-87.7 0.5-93.8 14.5-78.7 0.2-0.9 
Ara h 2      
Mean SIgE  5.85 0.02 12.8 75.8 33.6 0.01 
Range 0-23.1 0-0.03 0-74 0.31->100 4.69-
>100 
0-0.04 
Mean BAT 24.2 0.75 22.3 37.3 48.4 0.12 
Range 0.1-71.8 0.3-1.3 0-88.4 0-87.0 7.2-79 0-0.7 
Ara h 8      
Mean SIgE  0.22 0.2 0.1 0.12 0.28 0.21 
Range 0-2.36 0-0.41 0-1.23 0-0.46 0-1.1 0-1.26 
Mean BAT 0.82 0.6 0.55 0.40 0.52 0.52 

































































Not Exposed Tolerant Mild Moderate Severe Controls
Peanut BAT by Severity Group
 










Not Exposed Tolerant Mild Moderate Severe Controls
Comparison of BAT Averages by Severity
mean of Whole Peanut (100ng/ml) mean of Ara h1(1000ng/ml)
mean of Ara h2(20ng/ml) mean of Ara h8(100ng/ml)





severe group which was actually lower than the moderate group.  Further investigation of 
the 5 severe patients showed that 1 patient had >100 kU/l to peanut and another 3 also 
had significantly higher than the accepted SIgE cut-off of >15kU/l for determining a 
peanut allergy.  The last patient, however, had much lower values of 4.38 kU/l to peanut 
which lowered the group mean.  This patient was a 5-year-old female with a reported 
history of anaphylaxis to peanut, monosensitization to Ara h 2 (4.69 kU/l), and a 
discordant SPT value of less than 5 mm to peanut.  Her BAT results were also unique in 
that she had a 90% activation of her basophils at 100ng/ml of peanut antigen, only 2 other 
patients had higher values of 90.5% and 91.2%, and she also had a positive 68.7% BAT 
upregulation when stimulated with 1000ng/ml of Ara h 1 antigen despite not being 
sensitized to Ara h 1—this was the only instance of a BAT being positive when there was 
no IgE sensitization in the whole study.  It is unclear whether this is a valid BAT result or 
whether there might have been contamination during the lab test.  Performing another 
BAT when the child comes in on her next appointment might help resolve this issue. 
There was also an outlier in the moderate severity group.  Three out of the 4 
moderate patients had >100 kU/l, but the last patient only had 0.63 kU/l to peanut.  This 
patient was a 1-year-old female with a clinical history of hives and respiratory problems 
when exposed to peanuts with a peanut SPT of 2 mm.  She also showed no positivity in 
the BAT tests.  Further investigation of her clinical history showed that she had an 
accidental peanut exposure a month previously that had required an Emergency Room 
visit.  It is possible that she was in a type of anergic state following that exposure.  
The BAT upregulation among the different groups increased steadily as severity 





by helping determine the severity of the peanut allergy.  The analysis of the BAT 
averages was done at the highest concentration of each allergen.  The negative controls 
and tolerant group all had mean BATs of <10% which was expected and supported the 
high specificity of BAT for true allergies.  The BAT means for whole peanut were 28.1, 
40.7, and 62.2% in the mild, moderate, and severe groups.  The BAT means for Ara h 1 
and Ara h 2 in the same groups were 17, 35.1, 50.6, and 22.3, 37.3, and 48.4%.  Since 
patients can have monosensitization to single components, statistical analysis of the 
means was not warranted for Ara h 1 and Ara h 2 and is not shown.  We did look at the 
individual patients in each group to see if any group had a stronger BAT response despite 
having lower IgE levels, but there was wide variability among all the patients and within 
each group.  The results are detailed in Table 5.3.  A good example of this wide  
Table 5.3 Component SIgE versus BAT by Severity Group 
        Individual Patients with SIgE Sensitization 
   #1 #2 #3 #4 #5 
Mild Symptoms 
     Ara h 1 IgE (kU/l) 
     Ara h 1 BAT (%) 
     Ara h 2 IgE (kU/l) 0.27 0.52 1.34 
  Ara h 2 BAT (%) 5.2 15.2 9.7     
Moderate Symptoms 
    Ara h 1 IgE (kU/l) 33.3 >100 >100 
  Ara h 1 BAT (%) 28.7 17.5 93.8 
  Ara h 2 IgE (kU/l) 0.31 >100 >100 >100 
 Ara h 2 BAT (%) 0.2 11 51.3 87   
Severe Symptoms 
    Ara h 1 IgE (kU/l) 6.42 13.6 33.9 57.9 
 Ara h 1 BAT (%) 31.2 60.1 14.5 78.7 
 Ara h 2 IgE (kU/l) 4.69 5.8 10.2 45.6 >100 





Figure 5.4 Correlation of SIgE Levels to BAT  
variability between SIgE and BAT is in the severe group which had 2 patients with 
~5kU/l IgE Ara h 2 sensitizations that produced BAT results of 24.5 and 72.0%. We also 
looked at the overall correlation of SIgE to BAT results regardless of severity group.  We 
felt this was important since SIgE is currently the only other serum test for allergies.  An 
analysis of each of the component SIgE levels compared to the BAT results of that 
allergen were done and are summarized in Figure 5.4 and Table 5.4.  There was not a 
strong correlation between the SIgE/BAT results for whole peanut and Ara h 2 (r ~0.5).  
Ara h 1 had a slightly stronger correlation (r~0.7) whereas Ara h 8 tended to have a 
negative correlation (r~ -0.13)  This is in line with the known fact that specific IgE only 
measure sensitization and that there can be patients with high levels of SIgE and no 






Table 5.4 Correlation Between SIgE and BAT 
 Total IgE  Peanut 
SIgE 
















0.45 0.49  Ara h 2 BAT 
(0.8ng/ml) 
0.45 0.44 
 Ara h1 IgE  Peanut 
SIgE 




Ara h 1 BAT 
(1000ng/ml) 
0.62 0.66  Ara h 8 BAT 
(100ng/ml) 
-0.19 -0.18 
Ara h 1 BAT 
(200ng/ml) 
0.71 0.69  Ara h 8 BAT 
(20ng/ml) 
-0.13 0.12 
Ara h 1 BAT 
(40ng/ml) 




Threshold levels were also found to have a marked difference between the  
different severity groups. Thirty-eight percent of the mild symptoms group had no 
response to any concentration of the whole peanut antigen.  In contrast, the 75% of the 
moderate symptoms group patients and 100% of the severe symptoms group had 
reactivity to at least one concentration of whole peanut. The percentage of patients 
responding to all concentrations of antigen also increased across the groups from 15.3% 
in the mild symptoms group to 25% in the moderate symptoms group to 60.0% in the 
severe symptoms group, suggesting that the more severe patients would react at lower 
concentrations of peanuts. 
Overall, there were 12 patients that had <10% activation to the whole peanut 
antigen and all of the other tested antigens.  Two of them were classified as tolerant and 





and 5 patients had never been exposed to peanut.  Then there was the moderate severity 
patient who was suspected of being in an anergic state.  The basophil upregulation in the 
mild and unexposed symptom group patients ranged from 0-5.8% which was well below 
the 10% cut-off.  Peanut challenges to confirm allergy status could be beneficial in these 
patients as long as the blood work did not show significantly high levels of SIgE to 
components that were not testing in the BAT, ie, Ara h 3, Ara h 6, and Ara h 9.  It is 
important to note, however, that those components should still be present in the whole 
peanut extract so to a certain degree so the BAT should still be somewhat predictive in 
those cases. 
The number of discrepant results was also looked at to ensure that the 10% cut-off 
functioned well and to see if there were significant problems with the BAT tests.  There 
were 22 cases where there was SIgE sensitization but no BAT upregulation and one case 
with BAT upregulation and no SIgE sensitization which was discussed earlier.  These 
cases are summarized in Table 5.5.  Two of the patients were our peanut challenge 
patients that had been proven to be tolerant to peanut and the discordant results were 
expected. Then there were 9 discrepant cases with whole peanut sensitization that ranged 
from 0.22 to 8.42 kU/l, 6 cases with Ara h 1 sensitization that ranged from 0.12 to 3.84 
kU/l, 5 cases of Ara h 2 sensitization that ranged from 0.15 to 0.87 kU/l, and 5 cases of 
Ara h 8 sensitization that ranged from 0.28-2.36 kU/l.  
 One patient, PBAT 021, has the highest values of SIgE sensitization 
discrepancies for peanut, Ara h 1, and Ara h 2 (8.42, 3.84, 0.87 kU/l, respectively). The 
corresponding BAT values are 5.8%, 2.3%, and 2.8% which are much higher than we 










BAT% Clinical Symptoms 
PBAT 017 Ara h 8 0.28 0.7% Anaphylaxis 
PBAT 018 Ara h 1 0.00 68.7% Anaphylaxis 
PBAT 019 Ara h 2 0.15 0.8% EOE 
PBAT 021 Peanut 8.42 5.8% Not Exposed 
 Ara h 1 3.84 2.3%  
 Ara h 2 0.87 2.8%  
PBAT 024 Peanut 0.80 0.9% Not exposed 
 Ara h 1 0.12 0.5%  
 Ara h 8 2.36 0.5%  
PBAT 025 Ara h 8 1.10 0.0% Respiratory Distress 
PBAT 026 Ara h 1 1.05 9.2% Hives, Swelling 
PBAT 028 Peanut 5.07 2.0% Hives 
 Ara h 1 0.12 2.0%  
PBAT 032 Ara h 1 2.10 8.2% Mouth tingling/itching 
PBAT 033 Peanut 0.57 0.2% Not exposed 
PBAT 034 Peanut 0.45 9.5% Hives, mouth swelling, 
itching 
PBAT 037 Peanut 0.23 2.5% Hives 
PBAT 038 Peanut 1.48 0.0% Oral Allergy Syndrome 
PBAT 041 Ara h 2 1.34 9.7% Itching, Rash 
PBAT 042 Ara h 8 0.46 0.3% Respiratory Distress 
PBAT 044 Peanut 0.22 1.2% Tolerant/Passed Challenge 
PBAT 047 Ara h 2 0.27 5.2% Hives, Throat Tightening 
PBAT 054 Peanut 





Hives, Respiratory issues 






the controls was 0.37%.  PBAT 021 has never been exposed to peanuts as far as we know 
so it is hard to determine if a true allergy exists and whether or not the result should be 
classified as a false negative.  A food challenge would also be beneficial in this case to 
correctly determine allergy status. 
All of the Ara h 8 sensitized patients were negative in this study, as previously 
noted, and all but 1 patient was polysensitized with the other peanut components.  The 
range of sensitization was also rather low and the highest sensitization was at 2.36 kU/l.  
In future studies, it might be beneficial to screen for those with higher levels (>15kU/l) to 
fully investigate whether Ara h 8 is capable of causing basophil activation in a 
polysensitized patient. 
There were 4 patients whose BAT values were 9.2%, 8.2%, 9.5%, and 9.7% that 
were extremely close to the 10% cut-off.  All 4 of the patients had convincing clinical 
history of symptoms to peanuts.  The next closest upregulations to those 4 patients were 
at 5.2 and 5.8 % activation and only one of those lower responding patients had a clinical 
history to peanut.  This, along with the mean BAT activation of <1% in the controls, 
indicates that the cut-off could be lowered to 8.0% and still retain good specificity for 
true peanut allergies.  An “Undetermined—Interpret with Caution” range could also be 
created for values that fall in between the background cut-off level of 2.5% and the 
positive cut-off level until more data can be gather on these low-responding patients. 
Stability Studies 
Stability studies to further evaluate the utility of BAT were performed during 





random.  The patient samples were tested within 9 hours of collection as per the 
research design.  Then the samples were kept at room temperature and the three BAT 
control tests (background, anti- FcRI, and fMLP) were repeated at approximately 24 
and 48 hours after the collection time.   
The mean basophil recovery was 582, 600, and 574 at original BAT test time, and 
at 24 hours, and 48 hours, respectively.  The recovery rate did not have a significant 
difference, p = 0.92 and p = 0.93 (t-test) between the different times and the background 
activation levels never went above 0.03 which was well below the 2.5% cut-off.  The 
change in the percentage of basophils responding to the controls was evaluated.  There 
was a mean overall decrease of 0.5% observed at 24 hours compared to the original BAT 
and a much greater mean decrease of 22% was noted at 48 hours.  The calculated sample 
size for determining if a difference occurs between the two points was eighteen samples 
which was not achieved so statistical significance was not calculated.  The lab values for 
the individual patients are shown in Table 5.6.  There was some variability between the 
patients, but overall, they showed similar trends. 
A responsiveness of at least 10% of basophils is needed to confirm an allergy.  If 
we allowed patient testing at 48 hours, it would, therefore, need to have greater than 32% 
upregulation at the time of collection.  Out of the 41 patients included in the final 
analysis, only 4 (9.8%) had an upregulation response of less than 32 % and greater than 
10% (nonresponder cut-off) when originally tested. This suggests that it could be possible 
to test patient samples from outlying clinics and hospitals within 24-48 hours and achieve 
a clinically relevant result in the majority of cases.  Larger stability studies looking at the 





Table 5.6 Stability of BAT Testing 
 PBAT #041 PBAT #042 NPBAT #005 Average 
Within 9 hours after collection    
Basophil Recovery 600, 600, 553 600,486, 600 600, 600, 600 582 
Background % 0.3 0.3 0.0 0.2 
FcϵRI CD63% 61.5 92 63.3 72.3 
fMLP CD63% 19 29.2 31.7 26.6 
At ~24 hours after collection    
Basophil Recovery 600, 600, 600 600, 600, 600 600, 600, 600 600 
Background % 0.3 0.2 0.2 0.2 
FcϵRI CD63% 68.5 87 59.8 71.8 
fMLP CD63% 38.5 64.3 52.5 51.8 
At ~48 hours after collection    
Basophil Recovery 600, 600, 600 600, 455, 515 600, 600, 600 574 
Background % 0.2 0.2 0 0.2 
FcϵRI CD63% 25.8 81.3 43.8 50.3 






















SIGNIFICANCE OF FINDINGS 
The goal of this study was to see if peanut allergy diagnosis, and by interference 
determination of severity, could be improved through the use of peanut component SIgE 
and BAT testing.  This study showed that BAT testing can improve allergy diagnosis and 
would be a beneficial tool for physicians.  In contrast to just using SIgE levels, the use of 
a basophil activation assay allows medical professionals to evaluate one of the main 
mechanisms of the allergic response rather than just evaluating the presence of SIgE.  
There were clear differences between atopic and true peanut allergy populations.  The 
mean whole peanut BAT % was <1% for the negative controls and the overall value for 
the allergic population was 32.9%.  When broken down by severity group, there were 
statistically significant differences in the peanut BAT means when compared to the atopic 
controls.  There was also a significant difference between the mild and severe symptom 
groups (p=0.04).  These are important findings and could help physicians predict how a 
child would react in a food challenge or prevent a food challenge from being done if the 
BAT suggests that they will have a strong allergic response that could be life-threatening.  
The research data also clearly show that patients with more severe allergies tended to 






determination of these allergen threshold levels can be used for monitoring oral 
immunotherapies, sublingual immunotherapy, and anti-IgE therapies.   
The BAT appears to have good specificity and sensitivity.  We only had one 
instance of a BAT being positive when there was no SIgE antibodies (2.3%) and none of 
the atopic controls had positive BAT’s despite having other allergies to tree nuts, 
shellfish, eggs, as well as atopic conditions like chronic hives, eczema, and mastocytosis.  
The major limitation of this study is that food challenges, the gold standard for 
determining allergy status, were not permitted so it is hard to determine true rates for 
false positive and false negative results, especially among those who have never been 
exposed to peanuts.  Skin prick tests, however, are also quite sensitive in predicting a 
severe response, although not as well as oral food challenges. 
The recruited sample population size of ~50 was based off of literature reviews of 
studies of a similar design to ours; however, the exclusion of the nonresponders and the 
need to sub-divide the patients into multiple groups left some groups with rather small 
sample sizes.  Further research and patient recruitment of those that have elect to undergo 
a food challenge could be done to improve upon the results and make a better 
determination of whether the BAT is capable of predicting a true allergy and the severity 
of the symptoms that would be seen.  These studies are currently being planned.  Another 
study that would be beneficial and is currently being planned is to incorporate a wider 
selection of Ara h 8 sensitized patients to determine if Ara h 8 truly is a minor allergen in 
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